- Previous Close
114.22 - Open
114.51 - Bid 91.16 x 800
- Ask 92.98 x 800
- Day's Range
91.08 - 114.71 - 52 Week Range
20.84 - 117.33 - Volume
7,311,483 - Avg. Volume
1,228,053 - Market Cap (intraday)
9.699B - Beta (5Y Monthly) 0.61
- PE Ratio (TTM)
74.74 - EPS (TTM)
1.23 - Earnings Date Apr 29, 2025 - May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
142.50
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
www.corcept.comRecent News: CORT
View More
Related Videos: CORT
Performance Overview: CORT
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CORT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CORT
View MoreValuation Measures
Market Cap
12.05B
Enterprise Value
11.67B
Trailing P/E
92.86
Forward P/E
60.98
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
19.20
Price/Book (mrq)
17.73
Enterprise Value/Revenue
17.29
Enterprise Value/EBITDA
84.42
Financial Highlights
Profitability and Income Statement
Profit Margin
20.92%
Return on Assets (ttm)
11.71%
Return on Equity (ttm)
23.81%
Revenue (ttm)
675.04M
Net Income Avi to Common (ttm)
139.73M
Diluted EPS (ttm)
1.23
Balance Sheet and Cash Flow
Total Cash (mrq)
383.33M
Total Debt/Equity (mrq)
1.02%
Levered Free Cash Flow (ttm)
183.85M
Research Analysis: CORT
View MoreResearch Reports: CORT
View MoreRaising target price to $76.00
CORCEPT THERAPEUTICS INC has an Investment Rating of BUY; a target price of $76.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice TargetWhat does Argus have to say about CORT?
CORCEPT THERAPEUTICS INC has an Investment Rating of BUY; a target price of $73.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice TargetRating increased to a BUY
CORCEPT THERAPEUTICS INC has an Investment Rating of BUY; a target price of $73.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice TargetLowering target price to $59.00
CORCEPT THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $59.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target